From: FDA Week
Nicholas Florko
***
Bruce Levinson, senior vice president of regulatory intervention at the Center for Regulatory Effectiveness, was hesitant to criticize FDA’s practices — adding that, “as a regulatory reform advocate, my first take is to be pleased,” given a number of recent changes to the unified agenda under Trump.
He noted that OMB’s Office of Information and Regulatory Affairs (OIRA), which oversees the unified agenda, sent a memo to federal agencies in March 2017 directing them to remove any items on the agenda that realistically will not be completed within 12 months.
Read Complete Article [paywall]